Traditional Chinese Medicine Erhuang Suppository for Treatment of Persistent High-risk Human Papillomavirus Infection and Its Impact on Transcriptome of Uterine Cervix

Abstract

Objective

High-risk human papillomavirus (HR-HPV) infection is the chief cause of cervical intraepithelial neoplasia (CIN) and cervical carcinoma. The Erhuang suppository (EHS) is a traditional Chinese medicine (TCM) prepared from realgar (As₂S₂), Coptidis rhizoma, alumen, and borneolum syntheticum and has been used for antiviral and antitumor purposes. However, whether EHS can efficiently alleviate HR-HPV infection remains unclear. This study was conducted to evaluate the efficacy of EHS for the treatment of persistent HR-HPV infection in the uterine cervix.

Methods

In this study, we evaluated the therapeutic efficacy of EHS in a randomized controlled clinical trial with a 3-month follow-up. Totally, 70 patients with persistent HR-HPV infection were randomly assigned to receive intravaginal administration of EHS or placebo. HPV DNA, ThinPrep cytologic test (TCT), colposcopy, and safety evaluation were carried out after treatment. Microarray analysis was performed to compare transcriptome profiles before and after EHS treatment. A K14-HPV16 mouse model was generated to confirm the efficiency of EHS.

Results

After 3 months, 74.3% (26/35) of the patients in the treatment group were HPV negative, compared to 6.9% (2/29) in the placebo group. High-throughput microarrays revealed distinct transcriptome profiles after treatment. The differentially expressed genes were significantly enriched in complement activation, immune response, and apoptotic processes. The K14-HPV16 mouse model also validated the remarkable efficacy of EHS.

Conclusion

This study demonstrated that EHS is effective against HR-HPV infection and cervical lesions. Additionally, no obvious systemic toxicity was observed in patients during the trial. The superior efficacy and safety of EHS demonstrated its considerable value as a potential cost-effective drug for the treatment of HPV infection and HPV-related cervical diseases.

References

[1] Cohen PA, Jhingran A, Oaknin A, et al.. Cervical cancer. Lancet, 2019, 393(10167): 169-182

[2] Yuan Y, Cai X, Shen F, et al.. HPV postinfection microenvironment and cervical cancer. Cancer Lett, 2021, 497: 243-254

[3] Hoffman SR, Le T, Lockhart A, et al.. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review. Int J Cancer, 2017, 141(1): 8-23

[4] Hewavisenti RV, Arena J, Ahlenstiel CL, et al.. Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk. Front Immunol, 2023, 14: 1112513

[5] Zheng Y, Li X, Jiao Y, et al.. High-Risk Human Papillomavirus Oncogenic E6/E7 mRNAs Splicing Regulation. Front Cell Infect Microbiol, 2022, 12: 929666

[6] Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med, 2018, 7(10): 5217-5236

[7] Crosbie EJ, Einstein MH, Franceschi S, et al.. Human papillomavirus and cervical cancer. Lancet, 2013, 382(9895): 889-899

[8] Bedell SL, Goldstein LS, Goldstein AR, et al.. Cervical Cancer Screening: Past, Present, and Future. Sex Med Rev, 2020, 8(1): 28-37

[9] Park IU, Introcaso C, Dunne EF. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis, 2015, 61(Suppl 8): S849-855

[10] Hallez S, Simon P, Maudoux F, et al.. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother, 2004, 53(7): 642-650

[11] Bogani G, V DID, Sopracordevole F, et al.. Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. Gynecol Oncol, 2020, 159(3): 636-641

[12] Giannini A, Di Donato V, Sopracordevole F, et al.. Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization. Vaccines, 2023, 11(3): 698

[13] Huang K, Zhang P, Zhang Z, et al.. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms. Pharmacol Ther, 2021, 225: 107843

[14] Dai YJ, Wan SY, Gong SS, et al.. Recent advances of traditional Chinese medicine on the prevention and treatment of COVID-19. Chin J Nat Med, 2020, 18(12): 881-889

[15] Zhuang Z, Wen J, Zhang L, et al.. Can network pharmacology identify the anti-virus and anti- inflammatory activities of Shuanghuanglian oral liquid used in Chinese medicine for respiratory tract infection?. Eur J Integr Med, 2020, 37: 101139

[16] Liu Y, Yang S, Wang K, et al.. Cellular senescence and cancer: Focusing on traditional Chinese medicine and natural products. Cell Prolif, 2020, 53(10): e12894

[17] Su XL, Wang JW, Che H, et al.. Clinical application and mechanism of traditional Chinese medicine in treatment of lung cancer. Chin Med J (Engl), 2020, 133(24): 2987-2997

[18] Wang S, Fu JL, Hao HF, et al.. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol Res, 2021, 170: 105728

[19] Feng C, Li A, Yin C, et al.. RealgarAlleviated Neuroinflammation Induced by High Protein and High Calorie Diet in Rats via the Microbiota-Gut-Brain Axis. Nutrients, 2022, 14(19): 3958

[20] Hollow SE, Johnstone TC. Realgar and arsenene nanomaterials as arsenic-based anticancer agents. Curr Opin Chem Biol, 2023, 72: 102229

[21] Luo L, Li C, Huang N, et al.. Traditional mineral medicine realgar and Realgar-Indigo naturalis formula potentially exerted therapeutic effects by altering the gut microbiota. Front Microbiol, 2023, 14: 1143173

[22] He L, Zhong Z, Chen M, et al.. Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers. Front Pharmacol, 2021, 12: 775084

[23] Huang J, Guo W, Cheung F, et al.. Integrating Network Pharmacology and Experimental Models to Investigate the Efficacy of Coptidis and Scutellaria Containing Huanglian Jiedu Decoction on Hepatocellular Carcinoma. Am J Chin Med, 2020, 48(1): 161-182

[24] Barabási AL, Oltvai ZN. Network biology: understanding the cell’s functional organization. Nat Rev Genet, 2004, 5(2): 101-113

[25] Wang Z, Qin X, Hu D, et al.. Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer. Cell Rep, 2022, 41(13): 111890

[26] Araldi RP, Sant’Ana TA, Mödolo DG, et al.. The human papillomavirus (HPV)-related cancer biology: An overview. Biomed Pharmacother, 2016, 106: 1537-1556

[27] Li R, Hou Y, Huang J, et al.. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res, 2020, 156: 104761

[28] Wang K, Chen Q, Shao Y, et al.. Anticancer activities of TCM and their active components against tumor metastasis. Biomed Pharmacother, 2021, 133: 111044

[29] Li L, Wang L, Xiao S, et al.. Effect of nanorealgar on proliferation and apoptosis of human cervical carcinoma cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban (Chinese), 2021, 40(10): 1068-1075

[30] Hu C, Liu T, Han C, et al.. HPV E6/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m(6)A-MYC expression. Int J Biol Sci, 2022, 18(2): 507-521

[31] Kwon OJ, Noh JW, Lee BC. Mechanisms and Effect of Coptidis Rhizoma on Obesity-Induced Inflammation: In Silico and In Vivo Approaches. Int J Mol Sci, 2021, 22(15): 8075

[32] Yang Y, Hua Y, Chen W, et al.. Therapeutic targets and pharmacological mechanisms of Coptidis Rhizoma against ulcerative colitis: Findings of system pharmacology and bioinformatics analysis. Front Pharmacol, 2022, 13: 1037856

[33] Kim SY, Park C, Kim MY, et al.. ROS-Mediated Anti-Tumor Effect of Coptidis Rhizoma against Human Hepatocellular Carcinoma Hep3B Cells and Xenografts. Int J Mol Sci, 2021, 22(9): 4797

[34] Wang N, Tan HY, Li L, et al.. Berberine and Coptidis Rhizoma as potential anticancer agents: Recent updates and future perspectives. J Ethnopharmacol, 2015, 176: 35-48

[35] Liang LN, Bai YY, Tang YZ, et al.. Contribution of Borneolum syntheticum to the Intervention Effect of Liuwei Dihuang Pill on Experimental Retinal Degeneration. Chin J Integr Med, 2018, 24(6): 442-447

[36] Abdul KS, Jayasinghe SS, Chandana EP, et al.. Arsenic and human health effects: A review. Environ Toxicol Pharmacol, 2015, 40(3): 828-846

[37] Chumduri C, Gurumurthy RK, Berger H, et al.. Opposing Wnt signals regulate cervical squamocolumnar homeostasis and emergence of metaplasia. Nat Cell Biol, 2021, 23(2): 184-197

[38] Deng B, Li A, Zhu Y, et al.. SHCBP1 contributes to the proliferation and self-renewal of cervical cancer cells and activation of the NF-κB signaling pathway through EIF5A. Oncol Lett, 2023, 25(6): 246

[39] Ma H, Han F, Yan X, et al.. PBK promotes aggressive phenotypes of cervical cancer through ERK/c-Myc signaling pathway. J Cell Physiol, 2021, 236(4): 2767-2781

[40] Kim J, Park S, Chang Y, et al.. Synergetic Effects of Intronic Mature miR-944 and ANp63 Isoforms on Tumorigenesis in a Cervical Cancer Cell Line. Int J Mol Sci, 2020, 21(16): 5612

[41] Marquard FE, Jücker M. PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. Biochem Pharmacol, 2020, 172: 113729

[42] Zeng J, He SL, Li LJ, et al.. Hsp90 upregulates PD-L1 to promote HPV-positive cervical cancer via HER2/PI3K/AKT pathway. Mol Med, 2021, 27(1): 130

[43] Bhattacharjee R, Das SS, Biswal SS, et al.. Mechanistic role of HPV-associated early proteins in cervical cancer: Molecular pathways and targeted therapeutic strategies. Crit Rev Oncol Hematol, 2022, 174: 103675

[44] Smith JA, Mathew L, Gaikwad A, et al.. From Bench to Bedside: Evaluation of AHCC Supplementation to Modulate the Host Immunity to Clear High-Risk Human Papillomavirus Infections. Front Oncol, 2019, 9: 173

[45] Chaberek K, Mrowiec M, Kaczmarek M, et al.. The Creation of the Suppressive Cancer Microenvironment in Patients with HPV-Positive Cervical Cancer. Diagnostics (Basel), 2022, 12(8): 1906

[46] Ferrall L, Lin KY, Roden RBS, et al.. Cervical Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res, 2021, 27(18): 4953-4973

[47] Dunkelberger JR, Song WC. Role and mechanism of action of complement in regulating T-cell immunity. Mol Immunol, 2010, 47(13): 2176-2186

[48] Shen YL, Jiang YP, Li XQ, et al.. ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway. Front Pharmacol, 2019, 10: 1596

[49] Bruno MT, Cassaro N, Mazza G, et al.. Spontaneous regression of cervical intraepithelial neoplasia 3 in women with a biopsy-cone interval of greater than 11 weeks. BMC Cancer, 2022, 22(1): 1072